An Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Japanese Subjects With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 25 Jun 2019
Price : $35 *
At a glance
- Drugs Roniciclib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 24 Jul 2018 Status changed from active, no longer recruiting to completed.
- 31 Jul 2017 Planned End Date changed from 27 Apr 2018 to 26 Apr 2019.
- 08 Feb 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.